© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
April 23, 2020
Looking at new data from the phase 3 PEARL trial, Dr. Melissa K. Accordino discusses how the use of CDK4/6 inhibitors could help patients with HR-positive/HER2-negative metastatic breast cancer move away from chemotherapy.
Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
Learning to be a Kinder Person After Cancer